These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19557456)

  • 1. [Aspects of the risks associated with vCJK from plasma derivatives from human plasma].
    Burger R; Offergeld R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):648-9. PubMed ID: 19557456
    [No Abstract]   [Full Text] [Related]  

  • 2. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products.
    Prowse C; Cuthbertson B; Turner M
    Haemophilia; 2011 Jul; 17(4):703. PubMed ID: 21362112
    [No Abstract]   [Full Text] [Related]  

  • 4. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
    Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
    Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A commentary on variant Creutzfeld-Jacob disease.
    Hoots K
    Haemophilia; 2010 Mar; 16(2):238-9. PubMed ID: 20487441
    [No Abstract]   [Full Text] [Related]  

  • 6. Recipients of blood or blood products "at vCJD risk".
    Bird SM
    BMJ; 2004 Jan; 328(7432):118-9. PubMed ID: 14726314
    [No Abstract]   [Full Text] [Related]  

  • 7. Removal of TSE agents from blood products.
    Foster PR
    Vox Sang; 2004 Jul; 87 Suppl 2():7-10. PubMed ID: 15209867
    [No Abstract]   [Full Text] [Related]  

  • 8. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products.
    Millar CM; Makris M
    Br J Haematol; 2012 Aug; 158(4):442-52. PubMed ID: 22775486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood safety and Creutzfeldt-Jakob disease.
    Wkly Epidemiol Rec; 1998 Jan 2-9; 73(1-2):6-7. PubMed ID: 9448481
    [No Abstract]   [Full Text] [Related]  

  • 10. Technical aspects of the development and validation of tests for variant Creutzfeldt-Jakob disease in blood transfusion.
    Minor PD
    Vox Sang; 2004 Apr; 86(3):164-70. PubMed ID: 15078250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 12. Prion diseases.
    Knight R
    Vox Sang; 2004 Jul; 87 Suppl1():104-6. PubMed ID: 15200617
    [No Abstract]   [Full Text] [Related]  

  • 13. Creutzfeldt-Jakob disease and blood products: FDA policy.
    Fratantoni JC
    Biologicals; 1998 Jun; 26(2):133-4. PubMed ID: 9811520
    [No Abstract]   [Full Text] [Related]  

  • 14. International views on universal leucodepletion: the perspective in NBS, England.
    Wallington T
    Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150
    [No Abstract]   [Full Text] [Related]  

  • 15. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 16. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B; Arrabal S
    Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creutzfeldt-Jakob disease.
    Clement P
    Haemophilia; 2000 Jul; 6 Suppl 1():68-78. PubMed ID: 10982271
    [No Abstract]   [Full Text] [Related]  

  • 18. Transfusion-related vCJD: prevention strategies for prion transmission.
    Holland PV
    Lijec Vjesn; 2007 May; 129 Suppl 3():46. PubMed ID: 18959066
    [No Abstract]   [Full Text] [Related]  

  • 19. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 20. The in vitro bioassay systems for the amplification and detection of abnormal prion PrP(Sc) in blood and tissues.
    Zhang W; Wu J; Li Y; Carke RC; Wong T
    Transfus Med Rev; 2008 Jul; 22(3):234-42. PubMed ID: 18572098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.